JNJ Quote, Financials, Valuation and Earnings

Gilead Sciences, Inc. has a net margin of 21.47% compared to Johnson & Johnson's net margin of 39.21%. Johnson & Johnson's return on equity of 33.27% beat Gilead Sciences, Inc.'s return on equity of 41.48%.

Johnson & Johnson has a consensus price target of $202.54, signalling downside risk potential of -1.36%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $130.63 which suggests that it could grow by 4.51%. Given that Gilead Sciences, Inc. has higher upside potential than Johnson & Johnson, analysts believe Gilead Sciences, Inc. is more attractive than Johnson & Johnson.

Johnson & Johnson has a beta of 0.357, which suggesting that the stock is 64.296% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.

Johnson & Johnson has a quarterly dividend of $1.30 per share corresponding to a yield of 2.5%. Gilead Sciences, Inc. offers a yield of 2.51% to investors and pays a quarterly dividend of $0.79 per share. Johnson & Johnson pays 84.8% of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences, Inc.'s is not.

Johnson & Johnson quarterly revenues are $24B, which are larger than Gilead Sciences, Inc. quarterly revenues of $7.8B. Johnson & Johnson's net income of $5.2B is higher than Gilead Sciences, Inc.'s net income of $3.1B. Notably, Johnson & Johnson's price-to-earnings ratio is 19.82x while Gilead Sciences, Inc.'s PE ratio is 19.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 5.40x versus 5.41x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of 21.47% compared to Johnson & Johnson's net margin of -19.69%. Johnson & Johnson's return on equity of 33.27% beat Moderna, Inc.'s return on equity of -30.18%.

Johnson & Johnson has a consensus price target of $202.54, signalling downside risk potential of -1.36%. On the other hand Moderna, Inc. has an analysts' consensus of $35.78 which suggests that it could grow by 42.09%. Given that Moderna, Inc. has higher upside potential than Johnson & Johnson, analysts believe Moderna, Inc. is more attractive than Johnson & Johnson.

Johnson & Johnson has a beta of 0.357, which suggesting that the stock is 64.296% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.

Johnson & Johnson has a quarterly dividend of $1.30 per share corresponding to a yield of 2.5%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Johnson & Johnson pays 84.8% of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Johnson & Johnson quarterly revenues are $24B, which are larger than Moderna, Inc. quarterly revenues of $1B. Johnson & Johnson's net income of $5.2B is higher than Moderna, Inc.'s net income of -$200M. Notably, Johnson & Johnson's price-to-earnings ratio is 19.82x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 5.40x versus 4.37x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protagonist Therapeutics, Inc. has a net margin of 21.47% compared to Johnson & Johnson's net margin of -834.87%. Johnson & Johnson's return on equity of 33.27% beat Protagonist Therapeutics, Inc.'s return on equity of 7.15%.

Johnson & Johnson has a consensus price target of $202.54, signalling downside risk potential of -1.36%. On the other hand Protagonist Therapeutics, Inc. has an analysts' consensus of $90.69 which suggests that it could grow by 5.37%. Given that Protagonist Therapeutics, Inc. has higher upside potential than Johnson & Johnson, analysts believe Protagonist Therapeutics, Inc. is more attractive than Johnson & Johnson.

Johnson & Johnson has a beta of 0.357, which suggesting that the stock is 64.296% less volatile than S&P 500. In comparison Protagonist Therapeutics, Inc. has a beta of 2.192, suggesting its more volatile than the S&P 500 by 119.221%.

Johnson & Johnson has a quarterly dividend of $1.30 per share corresponding to a yield of 2.5%. Protagonist Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Johnson & Johnson pays 84.8% of its earnings as a dividend. Protagonist Therapeutics, Inc. pays out -- of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Johnson & Johnson quarterly revenues are $24B, which are larger than Protagonist Therapeutics, Inc. quarterly revenues of $4.7M. Johnson & Johnson's net income of $5.2B is higher than Protagonist Therapeutics, Inc.'s net income of -$39.3M. Notably, Johnson & Johnson's price-to-earnings ratio is 19.82x while Protagonist Therapeutics, Inc.'s PE ratio is 135.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 5.40x versus 26.40x for Protagonist Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 21.47% compared to Johnson & Johnson's net margin of 38.89%. Johnson & Johnson's return on equity of 33.27% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Johnson & Johnson has a consensus price target of $202.54, signalling downside risk potential of -1.36%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $768.36 which suggests that it could grow by 6.18%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Johnson & Johnson, analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Johnson & Johnson.

Johnson & Johnson has a beta of 0.357, which suggesting that the stock is 64.296% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Johnson & Johnson has a quarterly dividend of $1.30 per share corresponding to a yield of 2.5%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.49% to investors and pays a quarterly dividend of $0.88 per share. Johnson & Johnson pays 84.8% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Johnson & Johnson quarterly revenues are $24B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Johnson & Johnson's net income of $5.2B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Johnson & Johnson's price-to-earnings ratio is 19.82x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Johnson & Johnson is 5.40x versus 5.60x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.